Adjuvant pembrolizumab versus high-dose interferon α-2b for Chinese patients with resected stage III melanoma: a retrospective cohort study
Conclusions Adjuvant pembrolizumab appeared to be as effective as IFN- α-2b in prolonging RFS in Chinese patients with resected stage III melanoma. Adjuvant pembrolizumab was associated with a lower rate of treatment-related AEs than IFN-α-2b. A prospective study is needed to confirm the clinical benefit of adjuvant pembrolizumab and determine dependable biomarkers.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Academies | Cancer | Cancer & Oncology | China Health | Drugs & Pharmacology | History of Medicine | Investigational New Drugs | Melanoma | Skin Cancer | Study